SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de diabétologie, nutrition, maladies métaboliques
Davies M.J., D'Alessio D.A., Fradkin J, et al., Management of hyperglycae-mia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)treatment. Diabetologia, 61, 2018, 2461–2498.
Scheen AJ., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitustreatment. Drugs, 75, 2015, 33–59.
Baker W.L., Smyth L.R., Riche D.M., et al., Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysistreatment. J Am Soc Hypertens, 8, 2014, 262–275 e9.
Ferrannini E, Muscelli E, Frascerra S, et al., Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientstreatment. J Clin Invest, 124, 2014, 499–508 [Erratum in: J Clin Invest 2014; 124:2287].
Scheen AJ., Historique des études cardiovasculaires : de l'UGDP … aux dernières étudestreatment. Médecine des maladies Métaboliques 11:Suppl.2 (2017), 2S15–2S26.
Scheen AJ., Etudes cardiovasculaires chez le patient diabétique de type 2 à risque : conclusions et impact des essais publiés en 2017-2018treatment. Médecine des maladies Métaboliques, 13(Suppl.1), 2019 (sous presse).
Zinman B, Wanner C, Lachin J.M., et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetestreatment. N Engl J Med, 373, 2015, 2117–2128.
Neal B, Perkovic V, Mahaffey K.W., et al., CANVAS Programme Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetestreatment. N Engl J Med, 377, 2017, 644–657.
Wiviott S.D., Raz I, Bonaca M.P., et al., DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetestreatment. N Engl J Med, 380, 2019, 347–357.
Zelniker T.A., Wiviott S.D., Raz I, et al., SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialstreatment. Lancet, 393, 2019, 31–39.
Wanner C, Inzucchi S.E., Lachin J.M., et al., EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetestreatment. N Engl J Med, 375, 2016, 323–334.
Perkovic V, de Zeeuw D, Mahaffey K.W., et al., Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trialstreatment. Lancet Diabetes Endocrinol, 6, 2018, 691–704.
Fitchett D, Inzucchi S.E., Lachin J.M., et al., EMPA-REG OUTCOME Investigators. Cardiovascular mortality reduction with empagliflozin in patients with type 2 diabetes and cardiovascular diseasetreatment. J Am Coll Cardiol, 71, 2018, 364–367.
Claggett B, Lachin J.M., Hantel S, et al., Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular diseasetreatment. Circulation, 138, 2018, 1599–1601.
Inzucchi S.E., Zinman B, Fitchett D, et al., How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trialtreatment. Diabetes Care, 41, 2018, 356–363.
Zinman B, Inzucchi S.E., Wanner C, et al., EMPA-REG OUTCOME® Investigators. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®treatment. Diabetologia, 61, 2018, 1522–1527.
Verma S, Mazer C.D., Fitchett D, et al., Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trialtreatment. Diabetologia, 61, 2018, 1712–1723.
Verma S, Mazer C.D., Al-Omran M, et al., Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOMEtreatment. Circulation, 137, 2018, 405–407.
Wanner C, Lachin J.M., Inzucchi S.E., et al., EMPA-REG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney diseasetreatment. Circulation, 137, 2018, 119–129.
Fitchett D, Butler J, van de Borne P, et al., EMPA-REG OUTCOME® trial investigators. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trialtreatment. Eur Heart J, 39, 2018, 363–370.
Fitchett D, Inzucchi S.E., Cannon C.P., et al., Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trialtreatment. Circulation, 2018 Dec 6. doi: 10.1161/ CIRCULATIONAHA.118.037778 [Epub ahead of print].
Scheen AJ., Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitorstreatment. Circ Res, 122, 2018, 1439–1459.
Scheen AJ., Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agoniststreatment. Diabetes Res Clin Pract, 143, 2018, 88–100.
Scheen AJ., Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetestreatment. Diabetes Metab, 2018 Oct 25. pii: S1262-3636(18)30197-6. doi: 10.1016/j. diabet.2018.10.003 [Epub ahead of print].
Wittbrodt E.T., Eudicone J.M., Bell K.F., et al., Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US populationtreatment. Am J Manag Care 24:8 Suppl (2018), S138–S145.
Birkeland K.I., Bodegard J, Norhammar A, et al., How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational studytreatment. Diabetes Obes Metab, 2018 Dec 9. doi: 10.1111/dom.13612[Epub ahead of print].
Arnold S.V., Inzucchi S.E., Tang F, et al., Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice projecttreatment. Eur J Prev Cardiol, 24, 2017, 1637–1645.
Kosiborod M, Cavender M.A., Fu A.Z., et al., CVD-REAL Investigators and Study Group. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)treatment. Circulation, 136, 2017, 249–259.
Cavender M.A., Norhammar A, Birkeland K.I., et al., CVD-REAL Investigators and Study Group. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REALtreatment. J Am Coll Cardiol, 71, 2018, 2497–2506.
Birkeland K.I., Jorgensen M.E., Carstensen B, et al., Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysistreatment. Lancet Diabetes Endocrinol, 5, 2017, 709–717.
Persson F, Nyström T, Jorgensen M.E., et al., Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes patients (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitors: A multinational observational studytreatment. Diabetes Obes Metab, 20, 2018, 344–351.
Kosiborod M, Lam C.S., Kohsaka S, et al., CVD-REAL Investigators and Study Group. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 studytreatment. J Am Coll Cardiol, 71, 2018, 2628–2639.
Toulis K.A., Willis B.H., Marshall T, et al., All-cause mortality in patients with diabetes under treatment with dapagliflozin: a population-based, open-cohort study in the Health Improvement Network Databasetreatment. J Clin Endocrinol Metab, 102, 2017, 1719–1725.
Udell J.A., Yuan Z, Rush T, et al., Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL population-based cohort study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)treatment. Circulation, 137, 2018, 1450–1459.
Suissa S., Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?treatment. Diabetes Care, 41, 2018, 6–10.
Verma S, Jüni P, Mazer CD., Pump, pipes, and filter: do SGLT2 inhibitors cover it all?treatment. Lancet, 393, 2019, 3–5.
Inzucchi S.E., Kosiborod M, Fitchett D, et al., Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic controltreatment. Circulation, 138, 2018, 1904–1907.
Scheen AJ., Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type2diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOMEtreatment. Diabetes Res Clin Pract, 121, 2016, 204–214.
Mudaliar S, Alloju S, Henry RR., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesistreatment. Diabetes Care, 39, 2016, 1115–1122.
Ferrannini E, Mark M, Mayoux E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesistreatment. Diabetes Care, 39, 2016, 1108–1114.
Heerspink H.J., Kosiborod M, Inzucchi S.E., Cherney DZ., Renoprotective effects of sodium-glucose cotransporter-2 inhibitorstreatment. Kidney Int, 94, 2018, 26–39.
Bonnet F, Scheen AJ., Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular diseasetreatment. Diabetes Metab, 44, 2018, 457–464.
Carlson C.J., Santamarina ML., Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitustreatment. Expert Opin Drug Saf, 15, 2016, 1401–1412.
Singh M, Kumar A., Risks associated with SGLT2 inhibitors: an overviewtreatment. Curr Drug Saf, 13, 2018, 84–91.
Lupsa B.C., Inzucchi SE., Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefitstreatment. Diabetologia, 61, 2018, 2118–2125.
Scheen AJ., An update on the safety of SGLT2 inhibitorstreatment. Expert Opin Drug Safety, 2019 (in press).
U.S. Food & Drug Administration. 2018 Safety Alerts for Human Medical Products. SGLT2 (sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area [Posted 08/29/2018].
Nadkarni G.N., Ferrandino R, Chang A, et al., Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysistreatment. Diabetes Care, 40, 2017, 1479–1485.
Bonora B.M., Avogaro A, Fadini GP., Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literaturetreatment. Diabetes Obes Metab, 20, 2018, 25–33.
Ueda P, Svanström H, Melbye M, et al., Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort studytreatment. BMJ, 363, 2018, k4365.
Tang H.L., Li D.D., Zhang J.J., et al., Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trialstreatment. Diabetes Obes Metab, 18, 2016, 1199–1206.
Bilezikian J.P., Watts N.B., Usiskin K, et al., Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagli-flozintreatment. J Clin Endocrinol Metab, 101, 2016, 44–51.
Inzucchi S.E., Iliev H, Pfarr E, Zinman B., Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trialtreatment. Diabetes Care, 41, 2018, e4–e5.
Ryan P.B., Buse J.B., Schuemie M.J., et al., Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)treatment. Diabetes Obes Metab, 20, 2018, 2585–2597.
Yuan, Z, DeFalco F.J., Ryan P.B., et al., Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort studytreatment. Diabetes Obes Metab, 20, 2018, 582–589.
Adimadhyam S, Lee T.A., Calip G.S., et al., Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort studytreatment. Diabetes Obes Metab, 20, 2018, 2792–2799.
Scheen AJ., Does lower limb amputation concern all SGLT2 inhibitors?treatment. Nat Rev Endocrinol, 14, 2018, 326–328.
Center for Drug Evaluation and Research. Application number: 20229300rg1s000. Summary Review for Regulatory Action [Signed/January 08, 2014]. https://www.accessdata.
Tang H, Dai Q, Shi W, et al., SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trialstreatment. Diabetologia, 60, 2017, 1862–1872.
Garber J, Abrahamson M.J., Barzilay J.I., et al., Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 Executive Summarytreatment. Endocr Pract, 25, 2019, 69–100.
NICE - National Institute for Health and Care Excellence. NICE Guideline [NG28]. Type 2 diabetes in adults: management. Last updated: April 2017. London: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng28.
Gunton JE, Cheung NW, Davis TM, st al. A new blood glucose management algorithm for type 2 diabetes. A position statement of the Australian Diabetes Society. Updated December 2016. Sydney: Australian Diabetes Society. https://diabetessociety.com.au/documents/ADS_POSITIONSTATEMENT_v2.4.pdf.
Diabetes Canada Clinical Practice Guidelines Expert Committee Lipscombe L, Booth G, Butalia S, et al., Pharmacologic Glycemic Management of Type 2 Diabetes in Adultstreatment. Can J Diabetes 42:Suppl.1 (2018), S88–S103 [Erratum in: Can J Diabetes 2018; 42:575, & Can J Diabetes 2018; 42:2018].
Société Suisse d'Endocrinologie et de Diabétologie (SGED/ SSED). Swiss Recommendations 2016 for the medical treatment of type 2 diabetes. Last updated: June 2017. www.sgedssed.ch/filead-min/files/6_empfehlungen_fachpersonen/61_richtlinien_fachaerzte/SGED_Recommendation_2016_English_final_mit_SGED_logo.pdf.
Scottish Intercollegiate Guidelines Network. SIGN 154 - Pharmalogical management of glycaemic control in people with type 2 diabetes: a national clinical guideline. November 2017. Edinburgh: Scottish Intercollegiate Guidelines Network. https://www.sign.ac.uk/assets/sign154.pdf.
Ponikowski P, Voors A.A., Anker S.D., et al., ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESCtreatment. Eur Heart J, 37, 2016, 2129–2200 [Erratum in: Eur Heart J 2018; 39:860].
Cosentino F, Ceriello, A, Baeres F.M., et al., Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtabletreatment. Eur Heart J, 2018 Nov 16. doi: 10.1093/eurheartj/ ehy677 [Epub ahead of print].
Gregg E.W., Li Y, Wang J, et al., Changes in diabetes-related complications in the United States, 1990-2010treatment. N Engl J Med, 370, 2014, 1514–1523.
McGurnaghan S, Blackbourn L.A., Mocevic E, et al., Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysistreatment. Diabet Med, 2018 Sep 23. doi: 10.1111/dme.13825 [Epub ahead of print].
Rao Kondapally Seshasai S Kaptoge S, Thompson A, et al., Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific deathtreatment. N Engl J Med, 364, 2011, 829–841 [Erratum in: N Engl J Med 2011; 364:1281].
Abtan J, Bhatt D.L., Elbez, Y, et al., REACH Registry Investigators. Residual ischemic risk and Its determinants in patients with previous myocardial infarction and without prior stroke or TIA: Insights from the REACH Registrytreatment. Clin Cardiol, 39, 2016, 670–677.
Fagot-Campagna A, Fosse S, Rouider C, et al., Comité scientifique d'En-tred. Caractéristiques, risque vasculaire et complications chez les personnes diabétiques en France métropolitaine : d'importantes évolutions entre Entred 2001 et Entred 2007treatment. Bull É pidémiol Hebd (BEH), 42-43, 2009, 450–455.
Cosker K, Denis P, Tala S, et al., groupe de travail de la cartographie des patients et des dépenses de la CnamTS. Pathologies associées, états de santé et traitements des personnes diabétiques en France : les données du Sniiram 2011treatment. Bull É pidémiol Hebd (BEH), 30-31, 2014, 507–514.
Rawshani A, Rawshani A, Franzén S, et al., Mortality and cardiovascular disease in type 1 and type 2 diabetestreatment. N Engl J Med, 376, 2017, 1407–1418.
Shah A.D., Langenberg C, Rapsomaniki E, et al., Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1-9 million peopletreatment. Lancet Diabetes Endocrinol, 3, 2015, 105–113.
Boonman-de Winter L.J., Rutten F.H., Cramer M.J., et al., High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetestreatment. Diabetologia, 55, 2012, 2154–2162.
Cavender M.A., Steg P.G., Smith S.C. Jr, et al., REACH Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registrytreatment. Circulation, 132, 2015, 923–931.
Caisse nationale de l'Assurance Maladie (CNAM). Améliorer la qualité du système de santé et maî triser les dépenses. Propositions de l'Assurance Maladie pour 2019. Rapport au ministre chargé de la Sécurité sociale et au Parlement sur l’évolution des charges et produits de l'Assurance Maladie au titre de 2019 (loi du 13 août 2004). Juillet 2018. Paris: CNAM. https://www.ameli.fr/espace-presse/communiques-et-dossiers-de-presse/les-derniers-communiques-de-la-caisse-nationale/detail-d-un-communique/3624.php.
van Dijk P.R., Kramer A, Logtenberg S.J., et al., Incidence of renal replacement therapy for diabetic nephropathy in the Netherlands: Dutch diabetes estimates (DUDE)-3treatment. BMJ Open, 5, 2015, e005624.
Haute Autorité de Santé (HAS). Fiche de synthèse - É valuation médico-économique des stratégies de prise en charge de l'insuffisance rénale chronique terminale en France. Octobre 2014. Saint-Denis La Plaine: Haute Autorité de santé. https://www.has-sante.fr/portail/upload/docs/application/pdf/2014-11/fiche_de_sytnhese_vf.pdf.
